NicOx preclinical data

In a mouse model of DMD, 10 and 21 mg/kg oral naproxcinod for 9 months significantly improved hind limb grip strength vs. 0.9 mg/kg prednisolone and led to a 25-30% reduction in inflammation in fore and hind limbs. Naproxcinod also led to significant improvements in heart function as measured by improved fraction shortening, ejection fraction and systolic blood pressure vs. prednisolone. NicOx also said that mice treated with naproxcinod did not show the long-term detrimental effects in skeletal and heart function that are typically seen with prednisolone. Data were presented at the Muscular Dystrophy Association meeting in Washington, D.C. ...